Related Experiment Video
Updated: Oct 12, 2025

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19
Jorge Monserrat1,2, Angel Asunsolo2,3,4, Ana Gómez-Lahoz1,2
1Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Insights
Elevated levels of certain cytokines and growth factors, including interleukin-10 (IL-10), interleukin-6 (IL-6), and granulocyte-colony stimulating factor (GCSF), predict intensive care unit (ICU) admission and death in severe COVID-19 patients.
Area of Science:
- Immunology
- Infectious Diseases
- Critical Care Medicine
Background:
- Severe COVID-19 is associated with a dysregulated immune response.
- Identifying biomarkers for predicting disease severity is crucial for patient management.
Purpose of the Study:
- To evaluate the predictive capacity of various cytokines and growth factors for ICU admission and mortality in severe COVID-19 patients.
Main Methods:
- Retrospective cohort study of 287 hospitalized COVID-19 patients.
- Serum levels of 62 immune response mediators were measured using Luminex Multiplex assay within six days of admission.
- Patients were followed for ICU admission and/or death.
Main Results:
- Increased serum levels of IL-6, IL-15, sRAGE, IP10, MCP3, sIL1RII, IL-8, GCSF, MCSF, and IL-10 were linked to ICU admission and/or death.
- The combination of IL-10, IL-6, and GCSF demonstrated the strongest prognostic value.
Conclusions:
- Severe COVID-19 leading to ICU admission or death is characterized by elevated inflammatory cytokines and chemokines.
- Serum IL-10, IL-6, and GCSF levels are highly prognostic for severe COVID-19 outcomes.
Objective:
To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19.
Design:
An observational, analytical, retrospective cohort study with longitudinal follow-up.
Setting:
Hospital Universitario Príncipe de Asturias (HUPA).
Participants:
287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020.
Main Outcome Measures:
Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16).
Results:
A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF.
Conclusions:
When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient's inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.
Related Concept Videos
Inflammatory Response I: Vascular and Cellular
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Myocarditis I: Introduction
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Pneumonia III: Complications and Assessment

